1. Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is > 2,500 pmoles/min/μg. 2. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) was 20 nM. 3. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) was 50 nM. 4. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) (ECD, aa 1-1297) was 33 nM. 5. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike-His (aa 1-760) was 12 nM.

DPP4/CD26 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 85.4 kDa and the accession number is P27487.

Human

HEK293 Cells

TP103,DPPIV,dipeptidylpeptidase 4,CD26,ADCP2,ADABP

The native mature form of human DPPIV (NP_001926.2) extracellular domain (Asn 29-Pro 766) was expressed and purified. Predicted N terminal: Asn 29

≥ 70 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.